Specifically, ISL chemosensitizes breast cancer stem cells by docking into the adenosine triphosphate (ATP) domain of GRP78 directly, which in turn suppresses β-catenin/ATP-binding cassette subfamily G2 (ABCG2) signaling [49]. The gene discussed is HSPA5; the disease is breast carcinoma.